171 related articles for article (PubMed ID: 19238009)
21. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
22. Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.
Tassi E; Facchinetti V; Seresini S; Borri A; Dell'antonio G; Garavaglia C; Casorati G; Protti MP
Clin Cancer Res; 2006 Aug; 12(16):4949-57. PubMed ID: 16914584
[TBL] [Abstract][Full Text] [Related]
23. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
[TBL] [Abstract][Full Text] [Related]
24. Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Brouwenstijn N; Gaugler B; Krüse KM; van der Spek CW; Mulder A; Osanto S; van den Eynde BJ; Schrier PI
Int J Cancer; 1996 Oct; 68(2):177-82. PubMed ID: 8900424
[TBL] [Abstract][Full Text] [Related]
25. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
26. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.
Cesana GC; DeRaffele G; Cohen S; Moroziewicz D; Mitcham J; Stoutenburg J; Cheung K; Hesdorffer C; Kim-Schulze S; Kaufman HL
J Clin Oncol; 2006 Mar; 24(7):1169-77. PubMed ID: 16505437
[TBL] [Abstract][Full Text] [Related]
27. An assessment of the immunological status of patients with renal cell carcinoma based on the relative abundance of T-helper 1- and -2 cytokine-producing CD4+ cells in peripheral blood.
Onishi T; Ohishi Y; Goto H; Tomita M; Abe K
BJU Int; 2001 Jun; 87(9):755-9. PubMed ID: 11412209
[TBL] [Abstract][Full Text] [Related]
28. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes.
Maeurer MJ; Martin DM; Castelli C; Elder E; Leder G; Storkus WJ; Lotze MT
Cancer Immunol Immunother; 1995 Aug; 41(2):111-21. PubMed ID: 7656270
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma.
Uzzo RG; Rayman P; Kolenko V; Clark PE; Bloom T; Ward AM; Molto L; Tannenbaum C; Worford LJ; Bukowski R; Tubbs R; Hsi ED; Bander NH; Novick AC; Finke JH
Clin Cancer Res; 1999 May; 5(5):1219-29. PubMed ID: 10353760
[TBL] [Abstract][Full Text] [Related]
30. Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles.
Maccalli C; Mortarini R; Parmiani G; Anichini A
Int J Cancer; 1994 Apr; 57(1):56-62. PubMed ID: 7908659
[TBL] [Abstract][Full Text] [Related]
31. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes.
Engels B; Noessner E; Frankenberger B; Blankenstein T; Schendel DJ; Uckert W
Hum Gene Ther; 2005 Jul; 16(7):799-810. PubMed ID: 16000062
[TBL] [Abstract][Full Text] [Related]
32. Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma.
Bernhard H; Maeurer MJ; Jäger E; Wölfel T; Schneider J; Karbach J; Seliger B; Huber C; Storkus WS; Lotze MT; Meyer zum Büschenfelde KH; Knuth A
Scand J Immunol; 1996 Sep; 44(3):285-92. PubMed ID: 8795723
[TBL] [Abstract][Full Text] [Related]
33. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
34. Increase in the capability of interleukin 2 gene-transduced renal cell carcinoma cells to induce cytotoxic lymphocytes.
Itoh K; Umezu Y; Morita T; Saya H; Seito D; Augustus LB; Nakao M; Sakata M; Miyajima J; Masuoka K
Kurume Med J; 1994; 41(2):53-63. PubMed ID: 7967440
[TBL] [Abstract][Full Text] [Related]
35. Definition of unique and shared T-cell defined tumor antigens in human renal cell carcinoma.
Brouwenstijn N; Hoogstraten C; Verdegaal EM; Van der Spek CW; Deckers JG; Mulder A; Osanto S; Schrier PI
J Immunother; 1998 Nov; 21(6):427-34. PubMed ID: 9807737
[TBL] [Abstract][Full Text] [Related]
36. Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens.
Mautner J; Jaffee EM; Pardoll DM
Int J Cancer; 2005 Jul; 115(5):752-9. PubMed ID: 15704175
[TBL] [Abstract][Full Text] [Related]
37. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
[TBL] [Abstract][Full Text] [Related]
38. Effects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma.
Han KH; Kim KW; Yan JJ; Lee JG; Lee EM; Han M; Cho EJ; Kang SS; Lim HJ; Koo TY; Ahn C; Yang J
BMC Urol; 2016 Jan; 16():2. PubMed ID: 26772545
[TBL] [Abstract][Full Text] [Related]
39. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.
Schendel DJ; Gansbacher B; Oberneder R; Kriegmair M; Hofstetter A; Riethmüller G; Segurado OG
J Immunol; 1993 Oct; 151(8):4209-20. PubMed ID: 8409397
[TBL] [Abstract][Full Text] [Related]
40. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
